These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Effect of aldose reductase inhibitor (Ponalrestat) on erythrocyte Na,K-ATPase activity in non-insulin-dependent diabetic patients with polyneuropathy. Umeda F; Noda K; Hashimoto T; Yamashita T; Nawata H Diabetes Res; 1989 Nov; 12(3):125-9. PubMed ID: 2561396 [TBL] [Abstract][Full Text] [Related]
7. Effects of ponalrestat, an aldose reductase inhibitor, on neutrophil killing of Escherichia coli and autonomic function in patients with diabetes mellitus. Boland OM; Blackwell CC; Clarke BF; Ewing DJ Diabetes; 1993 Feb; 42(2):336-40. PubMed ID: 8425670 [TBL] [Abstract][Full Text] [Related]
8. Short term effect of an aldose reductase inhibitor on urinary albumin excretion rate (UAER) and glomerular filtration rate (GFR) in type 1 diabetic patients with incipient nephropathy. Ranganathan S; Krempf M; Feraille E; Charbonnel B Diabete Metab; 1993; 19(2):257-61. PubMed ID: 8339858 [TBL] [Abstract][Full Text] [Related]
9. Metabolic effects of aldose reductase inhibition in diabetic man. Krentz AJ; Ellis SH; Hardman M; Nattrass M Diabetes Res; 1992 Jan; 19(1):41-8. PubMed ID: 1468186 [TBL] [Abstract][Full Text] [Related]
11. Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study. Goto Y; Hotta N; Shigeta Y; Sakamoto N; Kikkawa R Biomed Pharmacother; 1995; 49(6):269-77. PubMed ID: 7579007 [TBL] [Abstract][Full Text] [Related]
12. The role of aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy. Florkowski CM Med J Aust; 1993 Nov; 159(10):711-2. PubMed ID: 8110237 [No Abstract] [Full Text] [Related]
13. Reproducibility of parameters for assessment of diabetic neuropathy. The French Group for Research and Study of Diabetic Neuropathy. Valensi P; Attali JR; Gagant S Diabet Med; 1993 Dec; 10(10):933-9. PubMed ID: 8306589 [TBL] [Abstract][Full Text] [Related]
14. [Tolrestat in the therapy of diabetic peripheral neuropathy: is this drug really useful?]. Daniele E; Coco MP Clin Ter; 1995 Dec; 146(12):793-99. PubMed ID: 8681499 [TBL] [Abstract][Full Text] [Related]
15. [Diabetic neuropathy: treatment trial with an aldose reductase inhibitor (Sorbinil)]. Christensen JE; Larsen AB; Gregersen G Ugeskr Laeger; 1987 Nov; 149(46):3111-4. PubMed ID: 3127975 [No Abstract] [Full Text] [Related]
16. Alpha-lipoic acid in the treatment of autonomic diabetic neuropathy (controlled, randomized, open-label study). Tankova T; Koev D; Dakovska L Rom J Intern Med; 2004; 42(2):457-64. PubMed ID: 15529636 [TBL] [Abstract][Full Text] [Related]
17. [Effects of the aldose reductase inhibitor on diabetic polyneuropathy--the efficacy of F wave measurement]. Shimada H; Miki T; Kyogoku I; Kawagishi T; Inaba M; Okuno Y; Nishizawa Y; Morii H No To Shinkei; 1998 Sep; 50(9):817-20. PubMed ID: 9789304 [TBL] [Abstract][Full Text] [Related]
18. Effect of Tolrestat on oesophageal transit time and cholecystic motility in type 2 diabetic patients with asymptomatic diabetic neuropathy. Fabiani F; De Vincentis N; Staffilano A Diabete Metab; 1995 Dec; 21(5):360-4. PubMed ID: 8586153 [TBL] [Abstract][Full Text] [Related]
19. A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. A preliminary report. Valensi P; Le Devehat C; Richard JL; Farez C; Khodabandehlou T; Rosenbloom RA; LeFante C J Diabetes Complications; 2005; 19(5):247-53. PubMed ID: 16112498 [TBL] [Abstract][Full Text] [Related]
20. Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy. Ramirez MA; Borja NL Pharmacotherapy; 2008 May; 28(5):646-55. PubMed ID: 18447661 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]